David C Hoaglin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7820518/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on timeâ€toâ€event outcomes. Pharmaceutical Statistics, 2023, 22, 20-33.	1.3	17
2	On the <i>Q</i> statistic with constant weights for standardized mean difference. British Journal of Mathematical and Statistical Psychology, 2022, 75, 444-465.	1.4	4
3	Network Meta-analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects From Induction and Bias of the Results. Clinical Gastroenterology and Hepatology, 2021, 19, 2219-2221.	4.4	Ο
4	Adjusting win statistics for dependent censoring. Pharmaceutical Statistics, 2021, 20, 440-450.	1.3	18
5	A Q statistic with constant weights for assessing heterogeneity in metaâ€analysisâ€. Research Synthesis Methods, 2021, 12, 711-730.	8.7	6
6	Letter to the Editor on detecting and dealing with heterogeneity in meta-analyses by Cordero and Dans Journal of Clinical Epidemiology, 2021, 138, 230.	5.0	0
7	Exploring consequences of simulation design for apparent performance of methods of meta-analysis. Statistical Methods in Medical Research, 2021, 30, 1667-1690.	1.5	7
8	The Win Ratio: On Interpretation and Handling of Ties. Statistics in Biopharmaceutical Research, 2020, 12, 99-106.	0.8	39
9	The win ratio: Impact of censoring and followâ€up time and use with nonproportional hazards. Pharmaceutical Statistics, 2020, 19, 168-177.	1.3	17
10	Estimation in metaâ€analyses of mean difference and standardized mean difference. Statistics in Medicine, 2020, 39, 171-191.	1.6	34
11	Estimation in meta-analyses of response ratios. BMC Medical Research Methodology, 2020, 20, 263.	3.1	9
12	The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring. Journal of Biopharmaceutical Statistics, 2020, 30, 882-899.	0.8	28
13	Did Phlegon Actually Use a Stem-and-Leaf Display?. American Statistician, 2020, 74, 211-211.	1.6	0
14	Methods for estimating betweenâ€study variance and overall effect in metaâ€analysis of odds ratios. Research Synthesis Methods, 2020, 11, 426-442.	8.7	29
15	Another Look at Meta-analysis. Chance, 2019, 32, 4-5.	0.2	0
16	Meta-analysis of Opioids for Chronic Pain. JAMA - Journal of the American Medical Association, 2019, 321, 1935.	7.4	2
17	Pitfalls of using the risk ratio in metaâ€analysis. Research Synthesis Methods, 2019, 10, 398-419.	8.7	40
18	Automatic extraction of quantitative data from ClinicalTrials.gov to conduct meta-analyses. Journal of Clinical Epidemiology, 2019, 105, 92-100.	5.0	26

DAVID C HOAGLIN

#	Article	IF	CITATIONS
19	Problems in Meta-Analysis of Comparative Effectiveness of Conservative Interventions for Nonspecific Chronic Spinal Pain. Journal of Pain, 2018, 19, 228-229.	1.4	0
20	Contribution to the discussion of "When should metaâ€analysis avoid making hidden normality assumptions?― Biometrical Journal, 2018, 60, 1083-1084.	1.0	0
21	Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. PLoS ONE, 2018, 13, e0197583.	2.5	63
22	Meta-Analysis of Odds Ratios. Medical Care, 2017, 55, 328-335.	2.4	82
23	Practical challenges of <i>I</i> ² as a measure of heterogeneity. Research Synthesis Methods, 2017, 8, 254-254.	8.7	13
24	A Flawed Meta-analysis? Similar Risk of Cardiopulmonary Adverse Events Between Propofol and Traditional Anesthesia for Gastrointestinal Endoscopy. Clinical Gastroenterology and Hepatology, 2017, 15, 1640.	4.4	4
25	Misunderstandings about <i>Q</i> and â€~Cochran's <i>Q</i> test' in metaâ€analysis. Statistics in Medicine, 2016, 35, 485-495.	1.6	200
26	Reply to Discussants. Statistics in Medicine, 2016, 35, 503-504.	1.6	1
27	Shortcomings of an approximate confidence interval for momentâ€based estimators of the betweenâ€study variance in randomâ€effects metaâ€analysis. Research Synthesis Methods, 2016, 7, 459-461.	8.7	9
28	Letter to the Editor on Cohen etÂal. (Letter commenting on: J Clin Epidemiol. 2015;68:299–306). Journal of Clinical Epidemiology, 2016, 69, 261-262.	5.0	0
29	We know less than we should about methods of metaâ€analysis. Research Synthesis Methods, 2015, 6, 287-289.	8.7	20
30	Are Members of Long-Lived Families Healthier Than Their Equally Long-Lived Peers? Evidence From the Long Life Family Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 971-976.	3.6	36
31	Assessment of Heterogeneity in Meta-analyses. JAMA - Journal of the American Medical Association, 2014, 312, 2286.	7.4	16
32	Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics. American Journal of Emergency Medicine, 2014, 32, 1195-1199.	1.6	21
33	Antigen-specific H1N1 influenza antibody responses in acute respiratory tract infections and their relation to influenza infection and disease course. Journal of Clinical Virology, 2014, 60, 367-373.	3.1	7
34	An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis and a problematic response. Expert Opinion on Pharmacotherapy, 2013, 14, 1705-1706.	1.8	2
35	An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis?. Expert Opinion on Pharmacotherapy, 2012, 13, 1077-1078.	1.8	2
36	Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value in Health, 2011, 14, 429-437.	0.3	606

#	Article	IF	CITATIONS
37	A modified random-effect procedure for combining risk difference in sets of 2×2 tables from clinical trials. Journal of the Italian Statistical Society, 1993, 2, 269-290.	0.1	20